Research Programme: genetically-engineered TIL therapies - Instil Bio
Alternative Names: CoStAR TIL Instil Bio; CoStAR-TILLatest Information Update: 17 May 2024
At a glance
- Originator Instil Bio
- Class Antineoplastics; Gene therapies; Immunotherapies; Tumour infiltrating lymphocyte therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer